IMU 1.89% 5.2¢ imugene limited

Phase 2 Trial Prep, page-4

  1. 2,882 Posts.
    lightbulb Created with Sketch. 12220
    Well - Medidata is certainly a highly credible partner. It's an indication that Imugene are very serious about the management of their Clinical Trials data. This is a highly professional operation - not the penny dreadful the market seems to regard it as.

    In the end it all comes down to results and whether those results are believable. Credibility is vital, and Imugene are taking the right steps to ensure their credibility.

    Now - back to waiting, lol.

    Dave
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.